600566 濟川藥業
按盤價 
26.700 +0.050 (+0.188%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 3,932,057 | -32.27% | 8,016,895 | 9,654,537 | 8,996,367 | 7,630,510 | |
| 減：營業總成本 | 2,887,619 | -25.58% | 5,388,666 | 6,516,458 | 6,620,728 | 5,862,687 | |
| 其中:營業成本 | 932,610 | -22.55% | 1,663,541 | 1,783,993 | 1,537,411 | 1,276,564 | |
| 財務費用 | (54,613) | -73.41% | (240,829) | (257,489) | (85,763) | (88,966) | |
| 資產減值損失 | (1,141) | -- | (2,882) | -- | -- | -- | |
| 公允價值變動收益 | 17,463 | -79.80% | 99,202 | 14,604 | (7,316) | 114,554 | |
| 投資收益 | 156,701 | 409.96% | 83,540 | 81,724 | 66,209 | 46,978 | |
| 其中：對聯營企業和合營企業的投資收益 | -- | -- | -- | 2,457 | 769 | 675 | |
| 營業利潤 | 1,255,128 | -40.79% | 2,862,890 | 3,258,136 | 2,423,498 | 1,932,826 | |
| 利潤總額 | 1,260,406 | -43.57% | 2,978,246 | 3,297,090 | 2,507,921 | 1,950,435 | |
| 減：所得稅費用 | 236,289 | -27.55% | 441,540 | 470,027 | 336,202 | 233,219 | |
| 淨利潤 | 1,024,117 | -46.31% | 2,536,706 | 2,827,063 | 2,171,719 | 1,717,216 | |
| 減：非控股權益 | 1,654 | -63.39% | 5,152 | 4,282 | 969 | (1,959) | |
| 股東淨利潤 | 1,022,463 | -46.27% | 2,531,554 | 2,822,781 | 2,170,750 | 1,719,176 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.110 | -46.38% | 2.760 | 3.080 | 2.440 | 1.940 | |
| 每股派息 (元) * | -- | -- | 2.090 | 1.300 | 0.880 | 0.680 | |
| 每股淨資產 (元) * | 15.021 | -1.61% | 15.951 | 14.482 | 12.299 | 10.150 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 26/12/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
